Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients With Hematological Malignancies and Subjected to Treatment With Immune-checkpoint Inhibitors

Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients With Hematological Malignancies and Subjected to Treatment With Immune-checkpoint Inhibitors

Retrospective / prospective observational study of endocrinological adverse events in hematologic patients treated with immunological checkpoint inhibitors

Inclusion Criteria:

Retrospective cohort

• patients aged> 18 years
• cyto-histological diagnosis of mature lymphoproliferative syndrome of B or T lymphocyte origin
• advanced stage of illness (relapsed or refractory)
• patients undergoing treatment with immune anticheckpoint antibodies.
• written informed consent

Prospective cohort

• patients aged> 18 years
• cyto-histological diagnosis of mature lymphoproliferative syndrome of B or T lymphocyte origin
• advanced stage of illness (relapsed or refractory)
• patients who are candidates for therapy with anticheckpoint immune antibodies (it is specified that this therapy is completely independent of the subject's participation in the study).
• written informed consent

Exclusion Criteria:

• Severe, acute and chronic medical or psychiatric disorders that may affect the interpretation of the study results or interfere with it.